Navigation Links
McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
Date:9/28/2011

FORT WASHINGTON, Pa., Sept. 28, 2011 /PRNewswire/ -- McNEIL-PPC, Inc. and its affiliate McNeil MMP, LLC (McNEIL) announced today that they have completed the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture in the United States from Merck Sharp & Dohme Corp. (Merck). The joint venture will be renamed McNeil Consumer Pharmaceuticals Co. and will continue to market products under the PEPCID®, MYLANTA®, and MYLICON® brands.

In addition, Johnson & Johnson Inc. through its McNeil Consumer Healthcare Division (McNeil Canada) has today acquired from Merck Canada Inc. its partnership interest in the Canadian joint venture.  McNeil Canada will continue to market and sell PEPCID®, 222® and FLEET ENEMA® in Canada.

Ownership of the manufacturing facility located in Lancaster, Pa., will also transfer to McNEIL-PPC, Inc.   These acquisitions will allow McNeil and McNeil Canada to enhance their positions in the United States and Canada, respectively, in the important digestive health category.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of McNEIL-PPC, Inc., Johnson & Johnson Inc. and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  McNEIL-PPC, Inc., Johnson & Johnson Inc. and Johnson & Johnson do not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE McNEIL-PPC, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. McNEIL-PPC, Inc. Announces Signing of Consent Decree Covering Manufacturing Facilities in Las Piedras, PR, Fort Washington, PA, and Lancaster, PA
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. U.S. Preventive Medicine Acquires Specialty Disease Management
5. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
6. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
7. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
8. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
9. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
10. Wound Management Technologies Acquires Resorbable Orthopedics
11. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):